NCT05265923View on ClinicalTrials.gov

A Study of CM310 in Patients With Moderate-to-Severe Atopic Dermatitis

PHASE3CompletedINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

April 22, 2022

Primary Completion Date

October 31, 2023

Study Completion Date

December 25, 2023

Conditions
Atopic Dermatitis
Interventions
DRUG

CM310

IL-4Rα monoclonal antibody

OTHER

Placebo

Placebo

Trial Locations (1)

Unknown

Peking University People's hospital, Beijing

Sponsors
All Listed Sponsors
lead

Keymed Biosciences Co.Ltd

INDUSTRY

NCT05265923 - A Study of CM310 in Patients With Moderate-to-Severe Atopic Dermatitis | Biotech Hunter | Biotech Hunter